Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2015

Open Access 01-12-2015 | Research

Aloperine executes antitumor effects against multiple myeloma through dual apoptotic mechanisms

Authors: He Wang, Shu Yang, Hong Zhou, Mingna Sun, Lingran Du, Minyan Wei, Meixia Luo, Jingzhu Huang, Hongzhu Deng, Yinghong Feng, Jun Huang, Yi Zhou

Published in: Journal of Hematology & Oncology | Issue 1/2015

Login to get access
Metadata
Title
Aloperine executes antitumor effects against multiple myeloma through dual apoptotic mechanisms
Authors
He Wang
Shu Yang
Hong Zhou
Mingna Sun
Lingran Du
Minyan Wei
Meixia Luo
Jingzhu Huang
Hongzhu Deng
Yinghong Feng
Jun Huang
Yi Zhou
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2015
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-015-0120-x

Other articles of this Issue 1/2015

Journal of Hematology & Oncology 1/2015 Go to the issue

RESEARCH ARTICLE

STUMP un“stumped”: anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion

Review

F-BAR family proteins, emerging regulators for cell membrane dynamic changes—from structure to human diseases

Research

Soluble NKG2D ligand promotes MDSC expansion and skews macrophage to the alternatively activated phenotype

Research Article

Particulate cytoplasmic structures with high concentration of ubiquitin-proteasome accumulate in myeloid neoplasms

Research

Quantitative evaluation of the immunodeficiency of a mouse strain by tumor engraftments

Research Article

Infused autograft lymphocyte-to-monocyte ratio and survival in T-cell lymphoma post-autologous peripheral blood hematopoietic stem cell transplantation
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits